December 2025
1. RIDEG O, Dergez T, Toth A, Tornoczky T, et al
   Validation of ancillary procedures on formalin liquid fixed aspiration cytologic samples: from minimum to maximum.
   Am J Clin Pathol. 2025;164:924-932.
   

   >> Share

   
   
2. THABET DM, Thabit DM
   Immunohistochemical expression of POC1A, NUF2, and Ki-67 in invasive ductal carcinoma of the breast.
   Am J Clin Pathol. 2025;164:890-907.
   

   >> Share

   
   November 2025
3. KORIE U, Ai D, Podany P, Zhang H, et al
   Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study.
   Am J Clin Pathol. 2025;164:704-711.
   

   >> Share

   
   October 2025
4. CORBIN HN, Neyaz A, Jones TE, Clark BZ, et al
   PRAME immunohistochemistry distinguishes breast secondary angiosarcoma from benign and atypical vascular lesions of the breast.
   Am J Clin Pathol. 2025;164:600-607.
   

   >> Share

   
   September 2025
5. LEE SE, Hsu SC, Hung TH, Ng KF, et al
   Collagenase type IV improves the quality of HER2 fluorescence in situ hybridization for breast cancers.
   Am J Clin Pathol. 2025;164:342-350.
   

   >> Share

   
   August 2025
6. ZILENAITE-PETRULAITIENE D, Rasmusson A, Valkiuniene RB, Laurinaviciene A, et al
   Reproducibility of Ki67 Haralick entropy as a prognostic marker in estrogen receptor-positive HER2-negative breast cancer.
   Am J Clin Pathol. 2025 Aug 9:aqaf081. doi: 10.1093.
   

   >> Share

   
   June 2025
7. HUNTER N, Han L, Corbin H, Konnick EQ, et al
   Clinicopathologic and molecular characterization of low-grade, early-stage, and HER2-positive invasive breast carcinoma.
   Am J Clin Pathol. 2025;163:854-865.
   

   >> Share

   
   
8. WILCOCK D, Sirohi D, Coleman JF, Adelhardt P, et al
   HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry.
   Am J Clin Pathol. 2025;163:837-846.
   

   >> Share

   
   May 2025
9. TSENG YA, Tamayo S, Abada E, Marketkar S, et al
   Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: Reasons for discordance and impact of a single training session.
   Am J Clin Pathol. 2025 May 23:aqaf043. doi: 10.1093.
   

   >> Share

   
   April 2025
10. YILDIZ B, Jean-Gilles J Jr, Giampoli EJ, Kovar-Peltz S, et al
    TRPS1 is a useful marker in differentiating metastatic breast carcinoma from pancreatic adenocarcinoma in fine-needle aspiration specimens.
    Am J Clin Pathol. 2025;163:581-585.
    

    >> Share

    
    March 2025
11. XU J, Accola MA, Rehrauer WM, Weisman PS, et al
    Pilomatrix-like breast carcinoma: A mammary analog of pilomatrix-like high-grade endometrioid carcinoma (PiMHEC).
    Am J Clin Pathol. 2025;163:388-394.
    

    >> Share

    
    May 2024
12. HARTSOUGH E, DeSimone MS, Lorenzo ME, Dias-Santagata D, et al
    Utilizing PTEN immunohistochemistry as a screening test for Cowden syndrome.
    Am J Clin Pathol. 2024;161:490-500.
    

    >> Share

    
    
13. KOWALEWSKI A, Klijanienko J
    Cytologic analysis of metaplastic breast carcinoma: Review of 66 cases diagnosed at the Institut Curie.
    Am J Clin Pathol. 2024;161:430-435.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share